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The missions of the American College of Cardiology and
the American Heart Association have been to ensure
optimal care to those with or at risk for developing cardio-
vascular disease (CVD). The cardiovascular specialist is
expected to contribute significantly to the treatment and
prevention of CVD in the setting of a rapidly growing field
of knowledge ranging from molecular and cellular mecha-
nisms to clinical outcomes. Over the past 2 decades, there
have been dramatic increases in knowledge concerning
specific risk factors in atherosclerosis, hypertension, throm-
bosis, and other forms of vascular dysfunction. Clinical trials
have proven that strategies aimed at the appropriate detec-
tion and modification of risk factors can slow progression of
atherosclerosis and hypertension and reduce the occurrence
of clinical events in both primary and secondary prevention
settings. More recently, it has been shown that atheroscle-
rosis can be stabilized or even modestly reversed. Finally, the
growing knowledge base of molecular genetics applied to
the study of the cardiovascular system has a potentially great
relevance to the future clinical practice of preventive cardio-
vascular medicine.
Despite the fact that clinical outcomes can be improved
by promotion of favorable life habits and behaviors and by
the proper use of drug treatment, the application of preven-
tive interventions in the clinical practice of cardiovascular
medicine is not optimal. Prevention of CVD, in both the
primary and secondary prevention setting, must no longer
be peripheral to the practice of the cardiovascular specialist.
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The cardiovascular specialist must become proficient in the
primary and secondary prevention of CVDs, including the
ability to recommend specific primary and secondary pre-
ventive measures and to identify patients with subclinical
CVD who may benefit from more aggressive risk factor
modification.
It is imperative that cardiovascular training programs
provide the necessary education and training to promote
best practices among their trainees, who bear the responsi-
bility to provide optimal preventive services to their patients.
This report outlines specific areas of knowledge and skills
necessary to achieve this goal and also defines required and
recommended standards to achieve this goal.
General Standards and Environment
There should be adequate faculty, both in number and expe-
rience, to conduct a training program in preventive cardiovas-
cular medicine. In addition to this, it is highly desirable for at
least some of the faculty to have expertise in vascular biology,
atherosclerosis, hypertension, disorders of lipid metabolism,
obesity and weight management, diet and nutrition, smoking
cessation, diabetes mellitus, thrombosis, clinical epidemiology,
cardiac rehabilitation, clinical pharmacology, genetics, and the
psychosocial aspects of CVD. Ideally, specific faculty in the
cardiovascular medicine training program should be able to
serve as topic-area experts in one or more of these specified
areas. This is important because the faculty should be able to
function as preventive cardiovascular medicine role models.
Mentoring is important for cardiovascular trainees in their
formative years, and prevention-oriented role models should
function in this capacity.
Content of the Training Program
Optimal knowledge and skills required for the practice of
CVD prevention are extensive and can be divided into 3 levels.
Level 1
Level 1 training should be required of all cardiovascular
specialists and includes exposure to the following topics.
General Content Areas
1. Cardiovascular biology
• Cellular mechanisms of atherosclerotic vascular disease
• Genetics
2. Clinical epidemiology
• Incidence and prevalence of CVD
• Relationship between risk factors/markers and CVD
outcomes
• Gender and racial differences (1)
• Population demographics (aging and socioeconomic
status) (2)
3. Biostatistics
• Analytical methods
• Software for basic analyses
4. Clinical trials
• Statistical analyses (tracking experimental data)
• Study design (including calculation of sample size)
and understanding of methodology
• Data collection
• Data safety and monitoring
• Meta-analyses
5. Outcomes research
• Medical economics
• Cost/benefit analyses
• Policy and legislation
6. Cardiovascular pharmacology
• Mechanism of action
• Safety profile
• Efficacy and indication
7. Behavioral and psychosocial aspects of CVD (3)
• Affective disorders (depression, anxiety)
• Compliance
• Behavior modification (coping)
8. Risk assessment
• Traditional risk factors
• Nontraditional risk factors (e.g., high-sensitivityC-reactive
protein [4], apolipoprotein B, lipoprotein [a])
• Advanced risk assessment (renal, hepatic, inflamma-
tory, and autoimmune related)
9. Assessment of subclinical atherosclerosis
• Coronary artery calcification (5–10)
• Carotid intima-media thickness (11–13)
• Ankle-brachial index (14,15)
10. Risk factor management
• Hypertension
• Lipids
• Nutrition
• Thrombosis
• Smoking
• Exercise
• Pre-diabetes, insulin resistance, metabolic syn-
drome, and diabetes mellitus
• Atherosclerosis reversal
11. Disease management
• Multidisciplinary approach
• Adherence
• Education of primary care physicians
Specific Content Areas
Exposure to specific content areas in CVD prevention is
essential. These specific areas, outlined in an ABC format
(16,17), must encompass diagnosis and treatment in both
primary and secondary prevention settings.
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AAntiplatelet/Anticoagulant Therapy
• Aspirin
• Clopidogrel (P2Y12 receptor antagonists)
• Warfarin sodium: use in patients with atrial fibrilla-
tion and/or left ventricular thrombus
Angiotensin Converting Enzyme Inhibitor (ACE-I)/
Angiotensin Receptor Blocker (ARB) Therapy
• ACE-I
• ARB
• ACE-I and ARB combination therapy
Antianginal/Anti-Ischemic Therapies
• Nitrates
• Beta blockers
• Calcium channel blockers
• Novel antianginals (i.e., ranolazine)
Atherothrombosis
• Hypercoagulable states/thrombosis
• Peripheral arterial disease
B
Blood Pressure Control
• Familiarity with the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure guidelines (18)
Beta-Blocker Therapy
• Antiarrhythmic, antianginal and sympatholytic effects
• Secondary prevention of CVD in patients with a
myocardial infarction, heart failure/left ventricular
systolic dysfunction or hypertension
C
Cholesterol Management
• Familiarity with National Cholesterol Education Pro-
gram guidelines for low-density lipoprotein-cholesterol,
high-density lipoprotein-cholesterol, and triglycerides (19)
Cigarette Smoking Cessation
• Role of tobacco in the development and progression of
CVD and as a predictor of future cardiovascular events
in persons with established coronary artery disease (20)
• Familiarity with combination, long-term behavioral
support and pharmacologic therapy with or without
nicotine replacement for smoking cessation
D
Diet and Weight Management
• Diet: Familiarity with appropriate cardiovascular dietary
choices and interventions for change in dietary habits
• Weight Management: Familiarity with definitions of
normal, overweight, and obese states and measures to
define abnormal weights (body mass index, waist:hip
ratio); association of weight and increased rates of
cardiovascular events, death, and development of
comorbid conditions (diabetes mellitus, hypertension,
hypercholesterolemia); caloric reductions and in-
creased activity to reach ideal body weight
Diabetes Mellitus and the Metabolic Syndrome
• Familiarity with these terms (as they relate to patients
with and without CVD); guidelines for diagnosis and
recommended interventions (lifestyle changes, clini-
cal pharmacotherapy)
• Role of diabetes mellitus as a potential risk factor for
CVD and accelerated rates of atherosclerosis (21)
E
Exercise/Cardiac Rehabilitation (22–24)
• Association of inadequate levels of exercise with risk
of cardiovascular events
• Role of cardiac rehabilitation for patients with
chronic stable angina pectoris, recent myocardial
infarction, recent coronary artery bypass graft surgery,
noncoronary heart surgery, cardiac transplant, and/or
left ventricular systolic function
Ejection Fraction
• Assessment for patients with known CVD
• Role of adjunctive therapies (aldosterone blockade,
digitalis, etc.) in patients with left ventricular systolic
function
Although detailed, it is important to realize that this list of
key measures should not be considered all-inclusive. The
field of cardiovascular prevention is ever changing, as
epidemiologic and clinical trial data accumulates. Because of
this, training programs should be oriented toward providing
the most up-to-date guidelines for all risk factors in the
primary and secondary prevention of CVD.
Level 1 training in these areas should ideally be under-
taken in a 1-month (or longer) rotation dedicated to
preventive cardiovascular medicine (Table 1). An acceptable
alternative would be a 3-month (or longer) clinical cardiol-
ogy rotation that allows concomitant exposure to a compre-
hensive cardiovascular rehabilitation program at least 1 day
each week. This would allow incorporation of a broad range
of preventive approaches in addition to the predominant
rehabilitation focus of physical exercise (11). Ideally, the
1-month rotation should include weekly attendance at a
cardiac rehabilitation program, a diabetes mellitus or endo-
crinology clinic, and a lipid disorders clinic.
As an alternative, training in these areas could be ob-
tained in consultative, inpatient, and outpatient rotations,
with additional didactic sessions focusing on cardiovascular
prevention topics. If the latter approach is taken, the time
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allotted should be equivalent to at least 1 month of full-time
training. Training program directors may also consider
supplementing clinical experiences with short courses de-
voted exclusively to preventive cardiovascular medicine or
risk factor evaluation and management.
Level 2
Level 2 training should achieve a level of expertise such that
the trainee could serve as an independent consultant to
other cardiovascular practitioners in the management of
cardiovascular risk factors. This should involve 6 to 12
months of training within the 36 months of a cardiovascular
training program and should include time for direct evalu-
ation of patients with advanced atherosclerosis, hyperten-
sion, hyperlipidemia, recurrent thrombosis, cardiac rehabil-
itation, or related subspecialty conditions.
Level 2 training should involve blocks of time spent in
hypertension, lipid, and diabetes clinics or services, periph-
eral vascular laboratories, and clinical and cardiac rehabili-
tation services with additional exposure to behavioral med-
icine, exercise physiology, clinical epidemiology, outcomes
research, and vascular biology. To achieve training at Level
2, aggregate training in preventive laboratories and services
should account for a minimum of 6 months of a typical
3-year training program in cardiovascular medicine.
Level 3
Level 3 requires advanced training to qualify as director of a
clinical service, research program, or both. Examples include
the director of a preventive cardiovascular medicine, hyper-
tension or lipid service; director of a cardiac rehabilitation
program, director of a vascular medicine laboratory; or a
trainee who obtains an MPH degree in clinical epidemiol-
ogy, outcomes research, or both.
Training at this level would require 1 year of a 36-month
training program. This level of experience may require
additional formal education and training beyond a basic
3-year program. Alternatively, 2 to 3 years in a vascular
biology laboratory or health services outcomes research/
clinical epidemiology program would be required to attain
expertise in these fields which would possibly lead to
achievement of an advanced degree.
The most effective preventive cardiovascular medicine
services incorporate the skills and knowledge of multiple
providers, including cardiovascular physicians, nurses, nurse
practitioners, physician assistants, dietitians, behavioral
medicine specialists, and exercise physiologists. They oper-
ate on principles of interdisciplinary and multidisciplinary
teamwork, and they use systemic approaches to patient care.
Although such programs are more effective than routine
cardiovascular practice, few training programs offer oppor-
tunities to learn these new skills. Programs interested in
offering Level 3 training should incorporate these new
concepts into the training program and trainees interested
in Level 3 training should seek programs that offer these
advanced approaches to patient care.
Evaluation
Whereas knowledge of preventive interventions and mech-
anisms has blossomed in the past 10 years, clinical practice
in this area lags behind in virtually all practice settings. Even
academic centers, where most trainees are taught, fail to
provide ideal preventive services to cardiovascular patients.
Evaluation of the training in preventive cardiovascular
medicine could logically include efforts by clinical programs
to evaluate their own clinical inputs and outcomes and
demonstrate commitment to ongoing quality improvement
in clinical prevention. Programs could also use the Adult
Clinical Cardiology Self-Assessment Program (ACCSAP)
education programs and examinations to ensure trainees
(and faculty) have acquired appropriate knowledge of pre-
ventive cardiovascular medicine.
This is a revision of the 2002 document that was written by
Phillip Greenland, MD, FACC—Chair; Edward D. Frohlich,
MD, FACC; C. Noel Bairey Merz, MD, FACC; and Richard
C. Pasternak, MD, FACC. We are especially indebted to the
valuable comments and suggestions by M. Dominique Ashen,
PhD, CRNP, and Matthew J. Budoff, MD.
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Cardiovascular physicians frequently encounter vascular dis-
eases. Atherosclerosis and thrombosis, in particular, are
systemic disorders with clinical manifestations in most
peripheral circulations. These and other vascular diseases
account for substantial cardiovascular morbidity and mor-
tality. Moreover, technological advances in imaging tech-
niques and catheter-based interventions have brought man-
agement of vascular diseases firmly into the sphere of the
cardiovascular specialist. Training in vascular medicine
should be incorporated in a cardiovascular fellowship in
order to accommodate the clinical demands of this contem-
porary paradigm. Accordingly, 3 levels of training in vascu-
lar medicine are described.
Level 1—Basic training in vascular medicine that all
fellows should receive to acquire a sufficient knowledge base
to care for many patients with vascular disease.
Level 2—Additional training for fellows who wish to
develop special expertise in evaluating and managing pa-
tients with vascular disease. This level does not include
training in catheter-based interventions.
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